Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Provectus Pharmaceuticals Inc. -- Ignore unavailable to you. Want to Upgrade?

To: dirkdiggler who wrote (11892)	4/18/2013 1:59:35 PM
From: NTTG	2 Recommendations Read Replies (1) \| Respond to of 13111

Dirk, I think you may have missed the point here.... PVCT is not set up to run late stage clinical trials. They do not have the medical, clinical trial, or regulatory background or staff for that level of work. It took them nearly 2 years to lock the data from an 80 patient PII trial, how would they ever be able to take on a PIII effort? Can you name a historically successful biotech company that only had 4 FTE employees heading into their first PIII trial? The business model here is to create the smallest data-set necessary to secure a license or partner deal for PV-10 (or the now almost mythical PH-10), or to sell the product(s) outright. Late stage trial costs will be borne by someone else. The recently failed NASDAQ bid illustrated how unsuccessful they would be funding a study in the open market, and so far no ink has dried on a partner deal that would provide the $ and personnel support they need. The only reason the company needs ongoing cash is to support salaries for MGT and to keep trying to sneak up on the 'right' minimum data set to attract the partner/buyer HELP they so desperately need.